Skip to main content
SpringerLink
Log in

Treatment-Free Remission in Chronic Myeloid Leukemia

  • Chapter
  • First Online:
Pathogenesis and Treatment of Leukemia

  • 452 Accesses

Abstract

Over the last decade, a medically supervised trial of tyrosine kinase inhibitor (TKI) discontinuation has become an important option for patients with chronic phase chronic myeloid leukaemia (CML). A successful attempt, termed ‘treatment-free remission’ (TFR), has enabled selected patients to remain off TKI therapy long-term and has now been integrated into international treatment guidelines. Approximately 40–65% of chronic phase CML patients who cease TKI while in sustained deep molecular response will be able to remain off TKI in major molecular response 12 months after drug discontinuation. Consequently, understanding the nuances and complexities of TFR is vital for physicians offering and guiding their patients through a TFR attempt. Within this chapter, we present the data underpinning the TFR strategy, including appropriate patient selection and logistics of molecular monitoring. The potential risks and benefits of a TFR attempt will also be discussed, as well as emerging predictors of a successful TFR attempt which may guide future practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.

    PubMed  Google Scholar 

  2. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–7.

    CAS  PubMed  Google Scholar 

  6. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96.

    CAS  PubMed  Google Scholar 

  7. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–7.

    CAS  PubMed  Google Scholar 

  9. Hughes TP, Saglio G, Larson RA, et al. Long-term outcomes in patients with chronic myeloid leukemia in chronic phase receiving frontline nilotinib versus imatinib: ENESTnd 10-year analysis. Blood. 2019;134(Supplement 1):440–53. https://doi.org/10.1038/s41375-020-01111-2.

    Article  CAS  Google Scholar 

  10. Weatherald J, Chaumais M-C, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J. 2017;50(1):1700217.

    PubMed  Google Scholar 

  11. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–57.

    CAS  PubMed  Google Scholar 

  12. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109(1):58–60.

    CAS  PubMed  Google Scholar 

  13. Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32(5):415–23.

    PubMed  Google Scholar 

  14. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, DeAngelo DJ, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore JO, Naqvi K, Oehler V, Pallera AM, Patnaik M, Pratz K, Pusic I, Rose MG, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia. (Version 2.2021). Fort Washington, PA. J Natl Compr Canc Netw. 2020;18(10):1385–415. https://doi.org/10.6004/jnccn.2020.00472020.

    Article  CAS  PubMed  Google Scholar 

  16. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17.

    CAS  PubMed  Google Scholar 

  17. Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29(5):1123–32.

    CAS  PubMed  Google Scholar 

  18. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423–32.

    CAS  PubMed  Google Scholar 

  19. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20(11):1925–30.

    CAS  PubMed  Google Scholar 

  21. Jain P, Kantarjian H, Patel KP, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016;127(10):1269–75.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Baccarani M, Castagnetti F, Gugliotta G, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia. 2019;33(5):1173–83.

    CAS  PubMed  Google Scholar 

  23. Pagani IS, Dang P, Saunders VA, et al. Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia. Leuk Lymphoma. 2020;61:1–3.

    Google Scholar 

  24. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24(10):1719–24.

    CAS  PubMed  Google Scholar 

  25. Mattarucchi E, Spinelli O, Rambaldi A, et al. Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. J Mol Diagn. 2009;11(5):482–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Bartley PA, Latham S, Budgen B, et al. A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. J Mol Diagn. 2015;17(2):185–92.

    CAS  PubMed  Google Scholar 

  27. Alikian M, Ellery P, Forbes M, et al. Next-generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients. J Mol Diagn. 2016;18(2):176–89.

    CAS  PubMed  Google Scholar 

  28. Sharplin K, Altamura H, Taylor K, Wellwood J, Taylor D, Branford S. Chronic myeloid leukaemia: the dangers of not knowing your BCR-ABL1 transcript. Leuk Res. 2019;87:106231.

    CAS  PubMed  Google Scholar 

  29. Mahon F, Boquimpani C, Kim D, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168(7):461–70.

    PubMed  Google Scholar 

  30. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35.

    CAS  PubMed  Google Scholar 

  31. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–22.

    CAS  PubMed  Google Scholar 

  32. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–30.

    CAS  PubMed  Google Scholar 

  33. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435(7046):1267–70.

    CAS  PubMed  Google Scholar 

  34. Ross DM, Masszi T, Gómez Casares MT, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018;144(5):945–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Kimura S, Imagawa J, Murai K, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haemat. 2020;7(3):e218–25.

    Google Scholar 

  36. Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528–35.

    PubMed  Google Scholar 

  38. Okada M, Imagawa J, Tanaka H, et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk. 2018;18(5):353–60.

    PubMed  Google Scholar 

  39. Shah NP, Garcia-Gutierrez V, Jimenez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61(3):650–9.

    CAS  PubMed  Google Scholar 

  40. Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6(7):e375–83.

    PubMed  Google Scholar 

  41. Shanmuganathan N, Braley JA, Yong ASM, et al. Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood. 2019;134(1):85–9.

    CAS  PubMed  Google Scholar 

  42. Rousselot P, Loiseau C, Delord M, Cayuela JM, Spentchian M. Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv. 2020;4(13):3034–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846–54.

    CAS  PubMed  Google Scholar 

  44. Shanmuganathan N, Hughes TP. Molecular monitoring in CML: how deep? how often? how should it influence therapy? Blood. 2018;132(20):2125–33.

    CAS  PubMed  Google Scholar 

  45. Ross DM, Hughes TP. Treatment-free remission in patients with chronic myeloid leukaemia. Nat Rev Clin Oncol. 2020;17(8):493–503.

    PubMed  Google Scholar 

  46. Sekhri A, Liu D, Rasul M, Ahmed N, Ahmed T, Seiter K. Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res. 2009;33(9):1291–3.

    PubMed  Google Scholar 

  47. Reikvam H, Skavland J, Gullaksen S-E, et al. Chronic myeloid leukemia relapsing 25 years after allogenic stem cell transplantation. Case Rep Hemat. 2018;2018:2045985.

    Google Scholar 

  48. Richter J, Söderlund S, Lübking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32(25):2821–3.

    PubMed  Google Scholar 

  49. Berger MG, Pereira B, Rousselot P, et al. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br J Haematol. 2019;187(3):337–46.

    CAS  PubMed  Google Scholar 

  50. Rea D, Nicolini FE, Tulliez M, et al. Prognostication of molecular relapses after dasatinib or nilotinib discontinuation in chronic myeloid leukemia (CML): a FI-LMC STOP 2G-TKI study update. Blood. 2019;134(Supplement 1):30.

    Google Scholar 

  51. Papalexandri A, Saloum R, Touloumenidou T, et al. Blast crisis of CML after TKI discontinuation in a patient with previous stable deep molecular response: is it safe to stop? HemaSphere. 2018;2(6):e157.

    PubMed  PubMed Central  Google Scholar 

  52. Berman E, Druker BJ, Burwick R. Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy. J Clin Oncol. 2018;36(12):1250–6.

    CAS  PubMed  Google Scholar 

  53. Madabhavi I, Sarkar M, Modi M, Kadakol N. Pregnancy outcomes in chronic myeloid leukemia: a single center experience. J Glob Oncol. 2019;5:1–11.

    PubMed  Google Scholar 

  54. Abruzzese E, Turkina AG, Apperley JF, et al. Pregnancy management in CML patients: to treat or not to treat? report of 224 outcomes of the European leukemia net (ELN) database. Blood. 2019;134(Supplement_1):498.

    Google Scholar 

  55. Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127(4):392–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133(22):2374–84.

    CAS  PubMed  Google Scholar 

  57. Sabnis HS, Keenum C, Lewis RW, et al. Growth disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2019;185(4):795–9.

    PubMed  Google Scholar 

  58. Millot F, Claviez A, Leverger G, Corbaciglu S, Groll AH, Suttorp M. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. Pediatr Blood Cancer. 2014;61(2):355–7.

    PubMed  Google Scholar 

  59. Giona F, Saglio G, Moleti ML, et al. Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia. Br J Haematol. 2015;168(2):305–8.

    CAS  PubMed  Google Scholar 

  60. de Bruijn CMA, Millot F, Suttorp M, et al. Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study. Br J Haematol. 2019;185(4):718–24.

    PubMed  Google Scholar 

  61. Borghi L, Galimberti S, Baratè C, et al. Chronic myeloid leukemia patient’s voice about the experience of treatment-free remission failure: results from the Italian sub-study of ENEST path exploring the emotional experience of patients during different phases of a clinical trial. Front Psychol. 2019;10:329.

    PubMed  PubMed Central  Google Scholar 

  62. Legros L, Nicolini FE, Etienne G, et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer. 2017;123(22):4403–10.

    CAS  PubMed  Google Scholar 

  63. Shanmuganathan N, Pagani SI, Ross D, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137(9):1196–207. https://doi.org/10.1182/blood.2020005514.

  64. Naoto T, Kaichi N, Chiaki N, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103(11):1835–42.

    Google Scholar 

  65. Atallah E, Schiffer CA, Radich JP, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2021;7(1):42–50.

    PubMed  Google Scholar 

  66. Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910–4.

    CAS  PubMed  Google Scholar 

  67. Bernardi S, Malagola M, Zanaglio C, et al. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med. 2019;8(5):2041–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Chen K-k, Du T-f, Xiong P-s, Fan G-h, Yang W. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis. Front Oncol. 2019;9:372.

    PubMed  PubMed Central  Google Scholar 

  69. Branford S, Yeung DT, Ross DM, et al. The adverse effect of high Sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment. Blood. 2014;124(21):816.

    Google Scholar 

  70. Claudiani S, Apperley JF, Gale RP, et al. e14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica. 2017;102(8):e297–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124(4):511–8.

    CAS  PubMed  Google Scholar 

  72. Branford S, Yeung DT, Ross DM, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19):3818–24.

    CAS  PubMed  Google Scholar 

  73. Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Onc. 2017;35(3):298–305.

    Google Scholar 

  74. Ross DM, Pagani IS, Shanmuganathan N, et al. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 2018;32(12):2572–9.

    CAS  PubMed  Google Scholar 

  75. Nicolini FE, Dulucq S, Boureau L, et al. Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clin Cancer Res. 2019;25(22):6606–13.

    CAS  PubMed  Google Scholar 

  76. Lee S-E, Choi SY, Song H-Y, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101(6):717–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Fujisawa S, Ueda Y, Usuki K, et al. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST trial). Int J Clin Oncol. 2019;24(4):445–53.

    CAS  PubMed  Google Scholar 

  78. Kumagai T, Nakaseko C, Nishiwaki K, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109(1):182–92.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia

    Naranie Shanmuganathan & David M. Ross

  2. Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia

    Naranie Shanmuganathan & David M. Ross

  3. Centre for Cancer Biology, SA Pathology, Adelaide, SA, Australia

    Naranie Shanmuganathan & David M. Ross

  4. Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia

    Naranie Shanmuganathan & David M. Ross

  5. School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA, Australia

    Naranie Shanmuganathan & David M. Ross

  6. School of Medicine, University of Adelaide, Adelaide, SA, Australia

    Naranie Shanmuganathan

  7. Australasian Leukaemia and Lymphoma Group (ALLG), Richmond, VIC, Australia

    Naranie Shanmuganathan & David M. Ross

  8. Department of Haematology, Flinders University and Medical Centre, Adelaide, SA, Australia

    David M. Ross

Authors
  1. Naranie Shanmuganathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David M. Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naranie Shanmuganathan .

Editor information

Editors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Harinder Gill

  2. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Yok-Lam Kwong

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shanmuganathan, N., Ross, D.M. (2023). Treatment-Free Remission in Chronic Myeloid Leukemia. In: Gill, H., Kwong, YL. (eds) Pathogenesis and Treatment of Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-99-3810-0_49

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-3810-0_49

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-3809-4

  • Online ISBN: 978-981-99-3810-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation